AGM
BIOTW

Alpine Global Management’s Biotech Acquisition Company Warrant BIOTW Stock Holding History

Alpine Global Management’s Portfolio BIOTW Stock Details BIOTW Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-103,502
Closed -$67K – 818
2021
Q4 		$67K Buy
+103,502
New +$71.8K 0.01% 701

Other funds holding BIOTW

RCM
Radcliffe Capital Management Bala Cynwyd, Pennsylvania $1.33B AUM 1.18% 1-Year Est. Return
LP
LMR Partners London, United Kingdom $45.4B AUM 60.68% 1-Year Est. Return
SCM
Segantii Capital Management Hong Kong $1.54B AUM 16.73% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.71B AUM 106.31% 1-Year Est. Return
HIM
HGC Investment Management Toronto, Ontario, Canada $451M AUM 8.78% 1-Year Est. Return
AC
Aristeia Capital Greenwich, Connecticut $4.82B AUM 24.94% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
CCP
Corbin Capital Partners New York $61.3M AUM 53.03% 1-Year Est. Return
KCM
Kingstown Capital Management New York $30.4M AUM 3.71% 1-Year Est. Return
QGA
Q Global Advisors Fort Worth, Texas $113M AUM 20.91% 1-Year Est. Return

Alpine Global Management's BIOTW Position: Q1 2022 in Review

Alpine Global Management sold out of Biotech Acquisition Company Warrant (BIOTW) in Q1 2022, closing a stake of 103,502 shares — an estimated $67K sold.

Alpine Global Management first reported a position in BIOTW in Q4 2021 and held it in 1 quarter. The position peaked at $67K in Q4 2021. 52 funds tracked by Wall St. Rank hold BIOTW as of Q1 2022.

  • Alpine Global Management reported no remaining Biotech Acquisition Company Warrant position as of Q1 2022 after selling out during the quarter.
  • Alpine Global Management sold 103,502 Biotech Acquisition Company Warrant shares in Q1 2022, an estimated $67K.
  • Alpine Global Management first reported a position in Biotech Acquisition Company Warrant in Q4 2021 and held it in 1 quarter.
  • Alpine Global Management's Biotech Acquisition Company Warrant position peaked at $67K in Q4 2021.
  • 52 funds tracked by Wall St. Rank held Biotech Acquisition Company Warrant as of Q1 2022.

Based on Alpine Global Management's 13F filing for Q1 2022, filed 13 May 2022.